“Cara expects that our current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund our currently anticipated operating plan into 2026. Our current operating plan reflects the impact of our prioritization announcement in January 2024 which includes costs related to our pivotal program in NP.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CARA:
- Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
- Options Volatility and Implied Earnings Moves Today, March 04, 2024
- Options Volatility and Implied Earnings Moves This Week, March 04 – March 07, 2024
- CARA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biotech Alert: Searches spiking for these stocks today
